Side-by-side financials for GDTC and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GDTC | LLY |
|---|---|---|
| Market cap | - | $1.070 T |
| US-listed rank | - | #10 |
| Revenue (latest FY) | - | $65.18B |
| Net income (latest FY) | - | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 120 | 989 |
Full pages: CytoMed Therapeutics Ltd and ELI LILLY & Co, or browse the full rankings.